CLINICAL TRIALS PROFILE FOR FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

505(b)(2) Clinical Trials for FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Dosage	NCT02372357 ↗	A New Dosing Regimen for Posaconazole Prophylaxis in Children Based on Body Surface Area	Completed	Institutul Clinic Fundeni	Phase 4	2012-02-01	A new prophylactic posaconazole dosing regimen of 120mg/m² tid is evaluated pharmacologically in children 13 years and younger, suffering from a hematologic malignancy.
New Dosage	NCT02372357 ↗	A New Dosing Regimen for Posaconazole Prophylaxis in Children Based on Body Surface Area	Completed	Institutul Clinic Fundeni Bucharest	Phase 4	2012-02-01	A new prophylactic posaconazole dosing regimen of 120mg/m² tid is evaluated pharmacologically in children 13 years and younger, suffering from a hematologic malignancy.
New Dosage	NCT02372357 ↗	A New Dosing Regimen for Posaconazole Prophylaxis in Children Based on Body Surface Area	Completed	Universitaire Ziekenhuizen Leuven	Phase 4	2012-02-01	A new prophylactic posaconazole dosing regimen of 120mg/m² tid is evaluated pharmacologically in children 13 years and younger, suffering from a hematologic malignancy.
New Indication	NCT04495608 ↗	Fluconazole in Hypercalciuric Patients With Increased 1,25(OH)2D Levels	Recruiting	Hospices Civils de Lyon	Phase 2	2021-01-13	Hypercalciuria is one of the most frequent metabolic disorders associated with nephrolithiasis and/or nephrocalcinosis leading to Chronic Kidney Disease (CKD) and bone complications in adults. Hypercalciuria can be secondary to increased intestinal absorption and/or increased renal distal tubular reabsorption of calcium due to increased active vitamin D, i.e. 1,25(OH)2D, levels. The management of hypercalciuria is challenging. Classic management based on hyperhydration and dietary advice has low impact on calciuria and therefore on CKD progression. Other strategies such as hydrochlorothiazide can be proposed, however with an uncertain medical benefit in view of side effects (hypokalemia, asthenia, potential cutaneous long-term side effects). Azoles are known to inhibit the 1α-hydroxylase and therefore decrease 1,25(OH)2D levels. These antifungal drugs are commonly used in neonates, infants and adults; pharmacokinetic data are well described. Recently, to improve azoles tolerance, fluconazole has been successfully reported to reduce calciuria in patients with CYP24A1 mutation (1 adult) or NPTIIc mutations (1 child), while maintaining a stable renal function. Based on these observations, the investigators hypothesize that fluconazole is effective to decrease and normalize calciuria in patients with hypercalciuria and increased 1,25(OH)2D levels. The primary objective is to demonstrate that fluconazole normalizes or decreases calciuria after 4 months of treatment in patients with hypercalciuria and increased 1,25(OH)2D levels. The secondary objectives aim to describe: - the effects of fluconazole on the evolution over time of the calcium/phosphate metabolism, - the evolution of renal function, - the cohort at Baseline and after 4 months of treatment period, - the safety of fluconazole, - the onset of potential mycological resistances, - and the treatment compliance. This is a prospective, interventional, national, randomized in 2 parallel groups (1:1), controlled versus placebo, double blind trial. This study will involve patients between 10 and 50 years of age suffering from nephrolithiasis and/or nephrocalcinosis with hypercalciuria (> 0.1 mmol/kg/d) and increased 1,25 (OH)2D levels (≥ 150 pmol/l) and 25-OH-D levels (≥50 nmol/L). FLUCOLITH study is a unique opportunity to develop a new indication of a well-known and not expensive drug (e.g. fluconazole) in rare renal diseases, the ultimate objective being the secondary prevention of CKD worsening in these patients. If the results of this proof-of-concept randomized controlled trial are positive, the investigators will propose an extension phase to evaluate the long term efficacy and safety of fluconazole on renal and bone parameters.
OTC	NCT05059145 ↗	A Clinical Trial for Chlorhexidine as Treatment for Vulvovaginal Candidiasis	Not yet recruiting	Karolinska Institutet	Phase 2	2021-10-01	The overall aim of this study is to investigate if vaginally applied 1% chlorhexidine gluconate (CHG) could be an alternative treatment to oral fluconazole (FLZ), both during an acute episode and as prophylaxis, against recurrent infections of vulvovaginal candidiasis (RVVC). RVVC is very common in fertile women. Up to six months of treatment with FLZ is recommended for RVVC. Over the last ten years, the use of FLZ has increased markedly in many countries. No major problems have been noted with resistance development, but there is concern that this will occur in the future and alternative treatments are requested. In recent years, it has emerged that flukonazol interacts with several different types of drugs that are common in the patient group; several antidepressants, pain relief at dysmenorrhea (NSAID) and oral contraceptives to name a few. In Sweden an over-the-counter vaginal cream consisting of 1% chlorhexidine gluconate (Hibitane®) is available with the indication antiseptic use in vaginal examinations, especially during childbirth. The product has been used for a long time in various gynecological and obstetric surgical procedures. Hibitane® is approved during pregnancy and the cream is usually well tolerated. Our research group has previously done an in vitro study in which we analyzed the effect of FLZ and CHG's ability to kill fungal cells and to break down existing biofilm or prevent new biofilm formation. The biofilm formation is an important stage for the fungal cells to attach to surfaces such as skin and mucosa and is considered a first step in the development of an infection. In the biofilm, the fungus can hide from the immune system and also to some extent for various treatments aimed against the fungus. The results of the study showed that CHG was better than FLZ both at killing the fungal cells and preventing new biofilm from forming and dissolving already established "old" biofilm. This effect is absolutely crucial for successful treatment with antimycotics. These encouraging results form the basis of the planned study. If CHG is at least as effective as FLZ with little impact on vaginal lactobacillus, with high tolerability and without cytotoxic effect on epithelial cells, the results of the study might lead to major benefits to the patients with reduced risk of systemic side effects such as drug interactions, development of drug resistance and reduced drug costs.

All Clinical Trials for FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000627 ↗	Pilot Study to Determine the Feasibility of Fluconazole for Induction Treatment and Suppression of Relapse of Histoplasmosis in Patients With the Acquired Immunodeficiency Syndrome	Completed	Pfizer	N/A	1969-12-31	To evaluate the use of fluconazole as (1) induction therapy in histoplasmosis, (2) maintenance therapy to prevent relapse of histoplasmosis. Histoplasmosis is a serious opportunistic infection in patients with AIDS. Fluconazole is a triazole antifungal agent that has been used successfully in the treatment of experimental histoplasmosis in animals, but has not been completely evaluated in patients for this use. It has been approved by the Food and Drug Administration for certain other fungal infections. Nevertheless, physicians are prescribing it to their patients with histoplasmosis. This is a pilot study to examine the role of fluconazole for treating histoplasmosis in AIDS patients.
NCT00000627 ↗	Pilot Study to Determine the Feasibility of Fluconazole for Induction Treatment and Suppression of Relapse of Histoplasmosis in Patients With the Acquired Immunodeficiency Syndrome	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	N/A	1969-12-31	To evaluate the use of fluconazole as (1) induction therapy in histoplasmosis, (2) maintenance therapy to prevent relapse of histoplasmosis. Histoplasmosis is a serious opportunistic infection in patients with AIDS. Fluconazole is a triazole antifungal agent that has been used successfully in the treatment of experimental histoplasmosis in animals, but has not been completely evaluated in patients for this use. It has been approved by the Food and Drug Administration for certain other fungal infections. Nevertheless, physicians are prescribing it to their patients with histoplasmosis. This is a pilot study to examine the role of fluconazole for treating histoplasmosis in AIDS patients.
NCT00000639 ↗	A Randomized Double Blind Protocol Comparing Amphotericin B With Flucytosine to Amphotericin B Alone Followed by a Comparison of Fluconazole and Itraconazole in the Treatment of Acute Cryptococcal Meningitis	Completed	Washington University School of Medicine	N/A	1969-12-31	To evaluate the effectiveness and safety of amphotericin B plus flucytosine (5-fluorocytosine) compared to amphotericin B alone for a first episode of acute cryptococcal meningitis in AIDS patients, and to compare the effectiveness and safety of fluconazole versus itraconazole. At least 10 percent of patients with a low CD4 count and HIV infection will develop meningitis due to Cryptococcus neoformans. More effective treatments than the standard therapy need to be explored.
NCT00000639 ↗	A Randomized Double Blind Protocol Comparing Amphotericin B With Flucytosine to Amphotericin B Alone Followed by a Comparison of Fluconazole and Itraconazole in the Treatment of Acute Cryptococcal Meningitis	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	N/A	1969-12-31	To evaluate the effectiveness and safety of amphotericin B plus flucytosine (5-fluorocytosine) compared to amphotericin B alone for a first episode of acute cryptococcal meningitis in AIDS patients, and to compare the effectiveness and safety of fluconazole versus itraconazole. At least 10 percent of patients with a low CD4 count and HIV infection will develop meningitis due to Cryptococcus neoformans. More effective treatments than the standard therapy need to be explored.
NCT00000676 ↗	Randomized Comparative Study of Fluconazole Versus Clotrimazole Troches in the Prevention of Serious Fungal Infection in Patients With AIDS or Advanced AIDS-Related Complex. (A Nested Study of ACTG 081)	Completed	Pfizer	Phase 3	1969-12-31	To study the effectiveness, safety, and tolerance of fluconazole versus clotrimazole troches (lozenges) as prophylaxis (preventive treatment) against fungal infections in patients enrolled in ACTG 081 (a study of prophylaxis against pneumocystosis, toxoplasmosis, and serious bacterial infection). Primarily, to compare the rates of invasive infections by C. neoformans, endemic mycoses, and Candida. To compare the mortality rates due to fungal infections between two antifungal prophylactic treatments. Secondarily, to assess the effect of prophylaxis on the incidence of severe fungal infections, defined as invasive infections and esophageal candidiasis and less severe mucocutaneous infection. Serious fungal infections are significant complicating and life-threatening occurrences in patients with advanced HIV infection. Oropharyngeal candidiasis is found in almost all such patients, and causes pain, difficulty in swallowing, and loss of appetite. Similarly, esophageal candidiasis causes illness in the population. Cryptococcosis, endemic mycoses, and coccidioidomycosis also cause significant illness and death in AIDS patients. Once established, fungal infections in AIDS patients generally require continuous suppressive therapy because attempts at curing these infections are usually unsuccessful. Fluconazole has a number of characteristics that would make it a logical candidate to examine as a prophylactic agent in patients with advanced HIV infection. Animal studies have shown it to be prophylactic in models of candidiasis, cryptococcosis, histoplasmosis, and coccidioidomycosis. Initial experience in patients with active cryptococcal meningitis appears favorable, and studies of oropharyngeal candidiasis show it to be effective.
NCT00000676 ↗	Randomized Comparative Study of Fluconazole Versus Clotrimazole Troches in the Prevention of Serious Fungal Infection in Patients With AIDS or Advanced AIDS-Related Complex. (A Nested Study of ACTG 081)	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 3	1969-12-31	To study the effectiveness, safety, and tolerance of fluconazole versus clotrimazole troches (lozenges) as prophylaxis (preventive treatment) against fungal infections in patients enrolled in ACTG 081 (a study of prophylaxis against pneumocystosis, toxoplasmosis, and serious bacterial infection). Primarily, to compare the rates of invasive infections by C. neoformans, endemic mycoses, and Candida. To compare the mortality rates due to fungal infections between two antifungal prophylactic treatments. Secondarily, to assess the effect of prophylaxis on the incidence of severe fungal infections, defined as invasive infections and esophageal candidiasis and less severe mucocutaneous infection. Serious fungal infections are significant complicating and life-threatening occurrences in patients with advanced HIV infection. Oropharyngeal candidiasis is found in almost all such patients, and causes pain, difficulty in swallowing, and loss of appetite. Similarly, esophageal candidiasis causes illness in the population. Cryptococcosis, endemic mycoses, and coccidioidomycosis also cause significant illness and death in AIDS patients. Once established, fungal infections in AIDS patients generally require continuous suppressive therapy because attempts at curing these infections are usually unsuccessful. Fluconazole has a number of characteristics that would make it a logical candidate to examine as a prophylactic agent in patients with advanced HIV infection. Animal studies have shown it to be prophylactic in models of candidiasis, cryptococcosis, histoplasmosis, and coccidioidomycosis. Initial experience in patients with active cryptococcal meningitis appears favorable, and studies of oropharyngeal candidiasis show it to be effective.

Clinical Trial Conditions for FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

Condition Name

Condition Name for FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Intervention	Trials
HIV Infections	42
Candidiasis	21
Mycoses	19
Meningitis, Cryptococcal	16

Condition MeSH

Condition MeSH for FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Intervention	Trials
Candidiasis	77
HIV Infections	45
Mycoses	45
Infections	31

Clinical Trial Locations for FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

Trials by Country

Trials by Country for FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Location	Trials
United States	771
China	36
Canada	28
Spain	20
Belgium	15

Trials by US State

Trials by US State for FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Location	Trials
California	57
Texas	55
Florida	46
New York	46
Pennsylvania	40

Clinical Trial Progress for FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

Clinical Trial Phase

Clinical Trial Phase for FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Clinical Trial Phase	Trials
PHASE4	6
PHASE3	4
PHASE2	4

Clinical Trial Status

Clinical Trial Status for FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Clinical Trial Phase	Trials
Completed	189
Recruiting	28
Unknown status	21

Clinical Trial Sponsors for FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

Sponsor Name

Sponsor Name for FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Sponsor	Trials
Pfizer	40
National Institute of Allergy and Infectious Diseases (NIAID)	25
National Cancer Institute (NCI)	7

Sponsor Type

Sponsor Type for FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Sponsor	Trials
Other	231
Industry	168
NIH	46

Fluconazole in Sodium Chloride 0.9% (Plastic Container) Clinical Trials Update, Market Analysis, and Pricing/Generic-Entry Outlook

Last updated: July 25, 2026

Fluconazole in 0.9% sodium chloride (IV, plastic container) is a niche formulation within the broader fluconazole market. The drug’s clinical evidence base is largely established for fluconazole itself (systemic antifungal), while the practical market question is formulation-level substitution risk, route-of-administration demand, and generic/alternative-infusion-solution coverage. Current competititor mapping and launch-risk assessment require an Orange Book–anchored product-level view and trial/program tracking for the specific IV presentation.

What clinical trials exist for fluconazole in sodium chloride 0.9% plastic container?

• No separate “product-specific” Phase 2/3 program is typically run for an IV solution presentation when bioequivalence and stability/compatibility support are available. Most new development focuses on (1) formulation stability, (2) container/closure systems, (3) compounding or administration usability, or (4) comparative PK/bioequivalence when regulators require it for a product change.
• Clinical trials that matter commercially are usually fluconazole IV vs IV alternatives in the treatment class (e.g., candidemia, invasive candidiasis, cryptococcal infections), not trials that randomize by diluent type or container material.

Which indications drive trial activity for systemic fluconazole?

Featured indication clusters that historically anchor fluconazole systemic trials:

• Invasive candidiasis and candidemia (including step-down strategies from IV to oral)
• Oropharyngeal and esophageal candidiasis
• Cryptococcal meningitis and other cryptococcal infections (including consolidation and maintenance settings)
• Prophylaxis in immunocompromised patients (oncology, transplant)

Are there recent trials tied to IV fluconazole formulations?

• Recent “clinical trial” visibility for IV fluconazole products is most often tied to registrational updates, new manufacturing sites, or non-inferiority comparisons to other antifungals in the same therapeutic space.
• For an IV sodium chloride solution in a plastic container, the highest-yield signal is not trial enrollment size but regulatory/labeling changes, supply availability, and generic substitution in hospital formularies.

What endpoints are used if a sponsor files a formulation-related study?

When a company runs a supporting study for an IV presentation, typical endpoints include:

• PK comparability (Cmax/AUC, clearance, half-life)
• Safety and tolerability in the defined infusion schedule
• Stability and compatibility (not always captured in clinical registries, but it drives approval risk and substitution uptake)

Market note: the market impact of this specific presentation is dominated by hospital purchasing patterns for IV antifungals and the availability/cost of equivalent generic fluconazole IV solutions.

---

What is the market size, demand drivers, and pricing power for IV fluconazole? The fluconazole market is segmented by:

• Route: oral vs IV
• Setting: hospital inpatient vs ambulatory infusion centers
• Indication mix: candidemia and invasive candidiasis are IV-heavy; step-down protocols drive transition to oral.

Why does the sodium chloride IV presentation matter commercially?

Even when the active ingredient is identical, the sodium chloride diluent presentation can affect:

• Pharmacy procurement and compounding workflows
• Compatibility with co-administered infusions in practice
• Nursing administration preference and product handling (container format and labeling)

Key demand drivers

• Increased volume of immunocompromised patients in hospitals
• Stewardship protocols that favor early antifungal treatment and standardized order sets
• Growth in hospital IV stewardship and “automatic substitution” policies once generics are stocked

Pricing pressure and cost-of-therapy logic

For mature antifungals like fluconazole:

• Price is typically anchored to the lowest formulary-available generic IV product
• Pricing power is reduced by (1) multiple generic suppliers, (2) therapeutic equivalence, and (3) interchangeable compounding rules in hospitals

Actionable market expectation: the IV presentation’s unit economics track generic competitive intensity and supply reliability more than clinical differentiation.

---

Who are the main manufacturers and how does competition shape share in IV fluconazole? The competitive landscape for IV fluconazole is usually dominated by multiple ANDA and authorized-generic entries across major wholesalers and group purchasing organizations.

Competitor archetypes that affect share

1. Multi-source generic manufacturers offering IV fluconazole in standard concentrations
2. Authorized generics supplied under licensing or distribution agreements
3. Alternative antifungal positioning (liposomal amphotericin B, echinocandins) that can shift IV demand share away from fluconazole for certain disease severities

What competes with fluconazole IV in hospital formularies?

• Echinocandins for invasive candidiasis and candidemia in many protocols
• Amphotericin B formulations in selected resistant or severe cases
• Fluconazole remains important when susceptibility, CNS indications, or step-down strategy supports its use

Net effect: fluconazole IV volume is sensitive to guideline adherence and local resistance patterns, but product substitution within fluconazole is usually easy.

---

When does exclusivity end for fluconazole IV solutions and what drives generic entry risk? For the active ingredient fluconazole, composition and method-of-use exclusivity is historically long expired. The remaining barriers, if any, are typically formulation/container-specific IP or process/manufacturing claims rather than active ingredient coverage.

How exclusivity typically works for older small-molecule APIs

• Original NDA exclusivity and new clinical study exclusivity are long finished
• For IV solutions, remaining restrictions usually come from:
  • Patents covering specific formulations or container-closure systems
  • Patents covering specific manufacturing processes or stability characteristics
  • Trade dress or labeling exclusivity, if any, which does not block generics long-term

Generic entry risk factors specific to an IV presentation

• Stability and compatibility claims in the Orange Book and scientific assessments
• Container-closure system differences (plastic vs glass; permeability considerations)
• Regulatory pathway complexity: supplement vs full ANDA if labeling or manufacturing changes are material

Commercial implication: once at least one generic equivalent is widely stocked, the marginal competitive entry usually drives price down rapidly.

---

What does the Orange Book status likely show for this IV product? For this specific presentation, Orange Book status must be product-linked. In most fluconazole IV solution categories:

• Multiple ANDA products are listed
• The most relevant patent listings are generally expired or near-expired
• The current constraint for market access is less “patent wall” and more “manufacturing capacity, distribution agreements, and formulary placement”

Practical impact: the product’s IP position typically does not create multi-year single-supplier dominance.

---

What patent estate would protect fluconazole in sodium chloride 0.9% IV solution? If protections exist, they typically fall into:

• Composition of matter for specific formulation parameters (rare for legacy fluconazole)
• Formulation patents covering the IV solution stability profile and excipient system
• Method-of-manufacture patents for the IV solution
• Container/closure patents (specific to permeability, leachables, or compatibility)

Litigation and Paragraph IV risk profile

For mature fluconazole:

• Paragraph IV challenges, if any, are more likely tied to legacy patent listings
• Litigation cadence is often resolved quickly into settlement or continued generic sales post-approval once patents expire

Actionable expectation: generic entry risk is usually low for long-term exclusivity, moderate for short-term supply continuity, and high for pricing compression.

---

What is the clinical differentiation versus alternative antifungals (echinocandins and amphotericin)? Fluconazole vs echinocandins:

• Fluconazole has strong activity for susceptible Candida species
• Echinocandins are often first-line in guidelines for many invasive candidiasis cases due to broad coverage and favorable safety profiles

Fluconazole vs amphotericin:

• Amphotericin is reserved for resistant cases or specific scenarios
• Fluconazole has a better toxicity profile in many circumstances

Commercial takeaway: fluconazole IV demand is guided by susceptibility testing and guideline protocols. The formulation in sodium chloride does not change clinical efficacy, so it mainly affects logistics and procurement.

---

How should hospitals and payers evaluate value for this specific IV presentation? Value drivers:

• Acquisition cost per gram of fluconazole
• Total cost of administration (handling, infusion setup)
• Stock availability and delivery reliability
• Pharmacy compatibility rules for co-infusion workflows

Procurement behavior:

• If multiple equivalent IV fluconazole generics are stocked, the sodium chloride plastic container presentation tends to be chosen on price and availability, not clinical differentiation.

---

Revenue and market projection: what is the forward outlook for IV fluconazole solutions? A reasonable market projection framework for IV fluconazole:

• Base demand growth tracks hospital admissions in at-risk populations and antifungal prescribing intensity
• Share of IV vs oral shifts with institutional protocols and pandemic-era care normalization
• Pricing trends follow generic competition and contracting dynamics

Outlook components that usually move the needle

• Generic pricing erosion after additional ANDA approvals
• Temporary supply disruptions that create short-term price spikes
• Formulary switches driven by group purchasing organization bidding cycles
• Institutional protocol updates moving more patients to echinocandins for certain invasive disease categories

Net projection: gradual demand stability with continuing downward price pressure unless there are supply constraints for specific generic SKUs in sodium chloride plastic containers.

---

What generic launch scenarios exist for fluconazole IV in plastic container? Generic launch pathways:

• ANDA approvals for equivalent IV fluconazole concentration and label
• “Branded generic” or authorized generic introductions through distributor contracts
• Manufacturing site supplements enabling additional capacity for the same presentation

Typical market effect by scenario

1. New multi-source generic enters widely:
   • Rapid price compression
   • Faster contracting and substitution
2. Entry with limited supply:
   • Short-term price resistance
   • Contract wins prioritize reliability
3. Entry but with pharmacy handling incompatibilities:
   • Slower uptake
   • Discounting needed for formulary consideration

---

How does product availability affect clinical outcomes and purchasing choices? For hospital antifungal therapy:

• Stockouts cause therapy delays and protocol deviations
• Pharmacy substitution rules are constrained by allowed therapeutics
• When IV fluconazole is unavailable, institutions often switch to therapeutically acceptable alternatives, shifting volume away from fluconazole

Commercial consequence: even without patent barriers, the provider ecosystem rewards suppliers with consistent supply.

---

Key Takeaways

• Clinical differentiation for fluconazole in sodium chloride 0.9% plastic container is usually driven by formulation/regulatory comparability rather than new outcomes trials.
• Market share and pricing are primarily shaped by multi-source generic competition, supply reliability, and formulary contracting cycles.
• For forward projections, the dominant risks are (1) price erosion from additional generics, (2) temporary supply constraints that can spike pricing, and (3) protocol shifts that affect IV fluconazole demand relative to echinocandins.
• Patent exclusivity for the active ingredient is largely not the constraint; any remaining barriers are formulation/process/container-specific and typically do not sustain long-term single-supplier dominance.

---

FAQs

1. Does sodium chloride 0.9% in plastic container change fluconazole efficacy versus other diluents?
2. What is the fastest pathway for a generic to enter IV fluconazole sodium chloride presentations?
3. How do hospitals choose between IV fluconazole generics during an antifungal shortage?
4. Do clinicians switch from IV fluconazole to oral fluconazole based on step-down protocols?
5. What tends to drive changes in formulary placement for IV antifungal solutions?

---

References

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed via FDA Orange Book database).
2. FDA. Approved Drug Products and FDA product labeling resources. (Accessed via FDA Drugs@FDA database).
3. ClinicalTrials.gov. Fluconazole interventional studies. (Search results accessed via ClinicalTrials.gov database).